Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 3Unknown 2Recruiting 1

Sponsor Class

OTHER_GOV 1OTHER 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 77Thoracic 44Other hematologic neoplasm 34CNS 17Gynecologic 9Myeloid 8Other solid neoplasm 7Genitourinary 7Breast 6Sarcoma 4Plasma cell 4Gastrointestinal 3NET 2Endocrine 2Dermatologic 2Classical hematology 2Tumor-Agnostic 1

Conditions

Neuroendocrine Tumors 1Gastro-enteropancreatic neuroendocrine tumor 1Carcinoma, Neuroendocrine 1

Interventions

lutetium Lu 177 dotatate 4lanreotide 3Temozolomide 3177Lu-octreotide, DOTA(0)-Tyr(3)- 3(177)Lu-DOTA-EB-TATE 3anlotinib 2Positron Emission Tomography Computed Tomography 2N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 2Metformin 2Everolimus 2Etoposide 2Cisplatin 2Capecitabine 2Biopsy 2surufatinib 1sintilimab 1regorafenib 1recombinant interferon alpha 2b-like protein 1pembrolizumab 1gallium Ga 68 dotatate 1copper dotatate CU-64 1cabozantinib 1amino-acid, glucose, and electrolyte solution 1Yttrium-90 1Tomography, Emission-Computed, Single-Photon 1Thalidomide 1Tegafur 1Surgical Procedures, Operative 1Somatostatin 1Rose Bengal B 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × Etoposide × NET × Clear all
NCT05076786 2021-11-03

Chidamide Plus Etoposide and Cisplatin/Carboplatin as First-line Treatment for Extrapulmonary Neuroendocrine Carcinoma

Peking Union Medical College Hospital

Phase 2 Unknown
28 enrolled
EndocrineNET

Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT03963193 2019-05-24

Etoposide/Cisplatin Compared With Irinotecan/Cisplatin for Advanced Gastrointestinal Neuroendocrine Tumor G3 Type

Henan Cancer Hospital

Phase 2 Unknown
112 enrolled
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡